证券代码：300529 证券简称：健帆生物 公告编号：2025-052 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于健帆转债回售的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 10、回售申报期内"健帆转债"暂停转股 11、"健帆转债"持有人有权选择是否进行回售，本次回售不具有强制性。 12、风险提示：（1）投资者选择回售等同于以 100.227 元/张（含息、税） 卖出持有的"健帆转债"。截至目前，"健帆转债"的收盘价格高于本次回 售价格，投资者选择回售可能会带来损失，敬请投资者注意风险。（2）在 "健帆转债"最后两个计息年度内，"健帆转债"持有人在每年回售条件首 次满足后可按上述约定条件行使回售权一次，若在首次满足回售条件而"健 帆转债"持有人未在公司公告的回售申报期内申报并实施回售的，该计息年 度不能再行使回售权，"健帆转债"持有人不能多次行使部分回售权。 1 1、债券简称：健帆转债 2、债券代码：123117 3、可转债面值：100 元/张 4、回售价格：100.227 元/张（含息、税） ...

Group 1 - The company issued 10 million convertible bonds with a total amount of RMB 1 billion, with a maturity of 6 years from June 23, 2021 [1] - The conversion price for the bonds is set at RMB 38.65 per share, and if the stock price falls below 70% of this price (RMB 27.06) for 30 consecutive trading days, the conditional redemption clause will take effect [1] - The bonds are currently in the conversion period, and the company has announced a conditional redemption due to the stock price situation [1] Group 2 - The company has applied to suspend the conversion of the bonds during the redemption application period, which will start on August 8, 2025, and last for 5 trading days until August 14, 2025 [2] - Normal trading of the bonds will continue during the suspension period, and conversion will resume on August 15, 2025 [2] - Bondholders are advised to pay attention to the announcement regarding the suspension and resumption of conversion [2]

Core Viewpoint - The company announces the conditional redemption of its convertible bonds ("健帆转债") due to the stock price being below the specified threshold for thirty consecutive trading days, allowing bondholders to redeem their bonds at a specified price [2][5]. Redemption Overview - The redemption condition is triggered when the stock price falls below 70% of the conversion price of 38.65 CNY, which is 27.06 CNY per share [2]. - Bondholders can redeem their bonds at face value plus accrued interest during the last two interest years of the bond [2][5]. Redemption Price Calculation - The redemption price is calculated to be 100.227 CNY per bond, which includes interest and tax [4]. - The interest rate for the fifth interest year is set at 1.80%, and the interest accrued over 46 days is calculated to be 0.227 CNY per bond [4]. Tax Implications - Individual investors and securities investment funds will have a 20% tax withheld on interest income, resulting in a net redemption amount of 100.182 CNY per bond [4]. - Qualified foreign institutional investors (QFII and RQFII) are exempt from tax, receiving the full redemption amount of 100.227 CNY [4]. Redemption Procedure - The company will announce the redemption details on the trading day following the triggering of the redemption condition, with daily reminders until the end of the redemption period [5]. - Bondholders must submit their redemption requests between August 8 and August 14, 2025, through the Shenzhen Stock Exchange trading system [5][6]. Trading and Conversion During Redemption Period - The convertible bonds will continue to trade during the redemption period, but conversion will be suspended [6]. - If bondholders submit multiple requests on the same trading day, the requests will be processed in the order of trading, redemption, and transfer [6].

中航证券有限公司 关于健帆生物科技集团股份有限公司 可转换公司债券回售有关事项的核查意见 中航证券有限公司（以下简称"保荐机构"、"中航证券"）作为健帆生物 科技集团股份有限公司（以下简称"健帆生物"、"公司"）向不特定对象发行 可转换公司债券的保荐机构。根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 15 号——可转换公司债券》等相关法律法规的规定，对健帆生物可转换公司债券（以 下简称"健帆转债"，债券代码：123117）回售有关事项进行了审慎核查，核查 情况及核查意见如下： 一、"健帆转债"发行上市情况 经中国证券监督管理委员会"证监许可【2020】3617 号"文核准，健帆生物 科技集团股份有限公司创业板向不特定对象发行 1,000.00 万张可转换公司债券， 该可转换公司债券于 2021 年 7 月 12 日起在深圳证券交易所上市交易。"健帆转 债"的存续起止日期为自 2021 年 6 月 23 日至 2027 年 6 月 22 日。 二、回售情况概述 根据《健 ...

债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 公告编号：2025-051 健帆生物科技集团股份有限公司 关于健帆转债暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123117 债券简称：健帆转债 2、证券代码：300529 证券简称：健帆生物 5、恢复转股时间：2025 年 8 月 15 日 经中国证券监督管理委员会"证监许可[2020]3617号"文同意注册，健帆生 物科技集团股份有限公司（以下简称"公司"）于2021年6月23日向不特定对象 发行了1,000.00万张可转换公司债券，每张面值100元，发行总额人民币100,000.00 万元，期限为自发行之日起6年，自2021年12月29日至2027年6月22日可转换为公 司股份，目前"健帆转债"处于转股期。 公司股票自 2025 年 6 月 23 日至 2025 年 8 月 1 日连续三十个交易日的收盘 价格低于当期"健帆转债"转股价格 38.65 元/股的 70%，即 27.06 元/股，且"健 帆转债"处于最后 ...

深圳市深南大道 6008 号特区报业大厦 24/31/41/42 层 邮编：518034 24/31/41/42F, Tequbaoye Building, 6008 Shennan Avenue, Shenzhen, Guangdong Province 518034, China 电话/Tel: (+86)(755) 83515666 传真/Fax: (+86)(755) 83515333 网址/Website:http://www.grandall.com.cn 邮箱/Email: grandallsz@grandall.com.cn 国浩律师（深圳）事务所 关于 健帆生物科技集团股份有限公司 可转换公司债券回售 之 法律意见书 GLG/SZ/A2061/FY/2025-932 致：健帆生物科技集团股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受健帆生物科技集团股份有 限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、和 《可转换公司债券管理办法》（以下简称"《管理办法》"）、深圳证券交易所上 市公 ...

债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于健帆转债回售的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300529 证券简称：健帆生物 公告编号：2025-050 根据《募集说明书》，有条件回售条款的约定如下： 1、有条件回售条款 本次发行的可转债最后两个计息年度内，如果公司股票在任意连续三十个交 易日的收盘价格低于当期转股价格的 70%，可转债持有人有权将其持有的可转 债全部或部分按债券面值加上当期应计利息的价格回售给公司。 若在上述交易日内发生过转股价格因发生派送股票股利、转增股本、增发新 股（不包括因本次发行的可转债转股而增加的股本）、配股以及派发现金股利等 情况而调整的情形，则在调整前的交易日按调整前的转股价格和收盘价格计算， 在调整后的交易日按调整后的转股价格和收盘价格计算。如果出现转股价格向下 修正的情况，则上述连续三十个交易日须从转股价格调整之后的第一个交易日起 重新计算。 10、回售申报期内"健帆转债"暂停转股 11、"健帆转债"持有人有权选择是否进行回售，本次回售不具有强制性。 ...

Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Jianfan Biological Technology Group Co., Ltd, indicating a recent increase in stock price and a low rolling PE ratio compared to the industry average [1][3] - As of March 31, 2025, the number of shareholders for Jianfan Biological has increased to 52,502, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of biomedical materials and high-tech medical devices, with a range of products including various blood purification devices and disinfectants [2] Group 2 - The latest financial results for the first quarter of 2025 show that Jianfan Biological achieved a revenue of 548 million yuan, representing a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71% from the previous year, with a gross profit margin of 80.74% [2] - The company ranks 52nd in the medical device industry based on its PE ratio of 26.63, while the industry average is 55.46 and the median is 37.74 [1][3] - Jianfan Biological has received multiple accolades, including recognition as a key high-tech enterprise under the National Torch Program and has established various research platforms, demonstrating its commitment to innovation and technology [2]

Group 1: Market Performance - The pharmaceutical sector showed strength in early trading on July 25, with the Biopharmaceutical ETF (159859) having a turnover rate exceeding 3.5% and a transaction volume of over 1.11 billion yuan, leading among its peers [1] - The Medical Devices ETF (159873) increased by 0.82% with a turnover rate over 8.1%, featuring stocks like Kangtai Medical hitting the daily limit [1] - The Innovation Drug ETF Tianhong (517380) rose by 0.79% with a turnover rate exceeding 1.8%, and its constituent stocks included Kanglong Chemical and WuXi Biologics, which saw significant gains [1] Group 2: ETF Characteristics - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors such as innovative drugs, CXO, vaccines, and blood products, making it the largest and most liquid product in its category [1] - The Innovation Drug ETF Tianhong (517380) is the largest in the market, spanning the Shanghai, Shenzhen, and Hong Kong markets, and is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovation Drug Select 50 Index, which has a cumulative weight of nearly 60% in its top ten constituents [2] Group 3: Industry Insights - Jianghai Securities emphasizes the importance of focusing on innovative drug companies with rich R&D pipelines and suggests investing in the entire innovative drug industry chain due to its potential for strong synergistic development [3] - Everbright Securities recommends focusing on two types of targets: those that have consistently been selected in centralized procurement and possess dual advantages in quality and cost, and innovative drug companies with rich R&D pipelines whose core products are entering medical insurance or are expected to be included in the innovative drug catalog [3]

Group 1 - The core business of the company is the research, production, and sales of biomaterials and high-tech medical devices, with major products including various blood purification devices and solutions [2] - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, a year-on-year decrease of 33.71%, with a gross profit margin of 80.74% [2] - The company has received multiple national and provincial recognitions, including being designated as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 24.60, while the average PE ratio for the medical device industry is 51.83, and the industry median is 37.23 [1][3] - The total market capitalization of the company is 17.817 billion yuan, ranking it 52nd in the industry based on PE ratio [1][3] - As of the first quarter of 2025, there are 12 institutions holding shares in the company, with a total holding of approximately 62.5493 million shares valued at 1.633 billion yuan [1]